Axogen President And CEO Karen Zaderej Plans To Retire From Company By January 2025
Author: Benzinga Newsdesk | January 04, 2024 05:41pm
The Company's Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Application (BLA) for Avance® Nerve Graft. While the transition is planned to be no later than Jan. 5, 2025, it could occur sooner depending on the timing of a new CEO appointment.
Posted In: AXGN